BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hayes AJ, Skouras C, Haugk B, Charnley RM. Keap1-Nrf2 signalling in pancreatic cancer. Int J Biochem Cell Biol 2015;65:288-99. [PMID: 26117456 DOI: 10.1016/j.biocel.2015.06.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Kankia IH, Paramasivan P, Elcombe M, Langdon SP, Deeni YY. Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00040] [Reference Citation Analysis]
2 Li K, Ouyang L, He M, Luo M, Cai W, Tu Y, Pi R, Liu A. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway. Oncotarget 2017;8:28865-79. [PMID: 28427200 DOI: 10.18632/oncotarget.15868] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
3 Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg 2021;25:315-27. [PMID: 34402431 DOI: 10.14701/ahbps.2021.25.3.315] [Reference Citation Analysis]
4 Zhou Y, Zhou Y, Wang K, Li T, Yang M, Wang R, Chen Y, Cao M, Hu R. Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett 2020;474:94-105. [PMID: 31954771 DOI: 10.1016/j.canlet.2020.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
5 Hara A, Endo S, Matsunaga T, Soda M, El-Kabbani O, Yashiro K. Inhibition of aldo-keto reductase family 1 member B10 by unsaturated fatty acids. Arch Biochem Biophys 2016;609:69-76. [PMID: 27665999 DOI: 10.1016/j.abb.2016.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guo Y, Shen L. Overexpression of NRF2 is correlated with prognoses of patients with malignancies: A meta-analysis. Thorac Cancer 2017;8:558-64. [PMID: 28766861 DOI: 10.1111/1759-7714.12462] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
7 Narayanan D, Ma S, Özcelik D. Targeting the Redox Landscape in Cancer Therapy. Cancers (Basel) 2020;12:E1706. [PMID: 32605023 DOI: 10.3390/cancers12071706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
8 Zhu J, Wang H, Chen F, Lv H, Xu Z, Fu J, Hou Y, Xu Y, Pi J. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity. Toxicol Appl Pharmacol 2018;358:1-9. [PMID: 30196066 DOI: 10.1016/j.taap.2018.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
9 Grattarola M, Cucci MA, Roetto A, Dianzani C, Barrera G, Pizzimenti S. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells. Free Radic Biol Med 2021;174:202-10. [PMID: 34364982 DOI: 10.1016/j.freeradbiomed.2021.08.006] [Reference Citation Analysis]
10 Hu Q, Qin Y, Xiang J, Liu W, Xu W, Sun Q, Ji S, Liu J, Zhang Z, Ni Q, Xu J, Yu X, Zhang B. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Cell Prolif 2018;51:e12456. [PMID: 29701272 DOI: 10.1111/cpr.12456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
11 Yang F, Li J, Deng H, Wang Y, Lei C, Wang Q, Xiang J, Liang L, Xia J, Pan X, Li X, Long Q, Chang L, Xu P, Huang A, Wang K, Tang N. GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. EMBO J 2019;38:e101964. [PMID: 31267557 DOI: 10.15252/embj.2019101964] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
12 Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib. Oxid Med Cell Longev 2017;2017:1864578. [PMID: 29410730 DOI: 10.1155/2017/1864578] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
13 Lu MC, Ji JA, Jiang ZY, You QD. The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev. 2016;36:924-963. [PMID: 27192495 DOI: 10.1002/med.21396] [Cited by in Crossref: 286] [Cited by in F6Publishing: 277] [Article Influence: 47.7] [Reference Citation Analysis]
14 Guo M, Zhou X, Han X, Zhang Y, Jiang L. SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis. Oncol Lett 2019;18:6899-908. [PMID: 31788129 DOI: 10.3892/ol.2019.11005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Xiang Y, Ye W, Huang C, Yu D, Chen H, Deng T, Zhang F, Lou B, Zhang J, Shi K, Chen B, Zhou M. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway. Oxid Med Cell Longev 2018;2018:2360427. [PMID: 29849873 DOI: 10.1155/2018/2360427] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
16 Zhang TT, Qu N, Sun GH, Zhang L, Wang YJ, Mu XM, Wei WJ, Wang YL, Wang Y, Ji QH, Zhu YX, Shi RL. NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer. Int J Oncol 2018;53:685-93. [PMID: 29901070 DOI: 10.3892/ijo.2018.4426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Endo S, Xia S, Suyama M, Morikawa Y, Oguri H, Hu D, Ao Y, Takahara S, Horino Y, Hayakawa Y, Watanabe Y, Gouda H, Hara A, Kuwata K, Toyooka N, Matsunaga T, Ikari A. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells. J Med Chem 2017;60:8441-55. [PMID: 28976752 DOI: 10.1021/acs.jmedchem.7b00830] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Nicco C, Batteux F. ROS Modulator Molecules with Therapeutic Potential in Cancers Treatments. Molecules 2017;23:E84. [PMID: 29301225 DOI: 10.3390/molecules23010084] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
19 Sun Q, Ye Z, Qin Y, Fan G, Ji S, Zhuo Q, Xu W, Liu W, Hu Q, Liu M, Zhang Z, Xu X, Yu X. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Oncogene 2020;39:6572-88. [PMID: 32929153 DOI: 10.1038/s41388-020-01452-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Purohit V, Wang L, Yang H, Li J, Ney GM, Gumkowski ER, Vaidya AJ, Wang A, Bhardwaj A, Zhao E, Dolgalev I, Zamperone A, Abel EV, Magliano MPD, Crawford HC, Diolaiti D, Papagiannakopoulos TY, Lyssiotis CA, Simeone DM. ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer. Genes Dev 2021;35:218-33. [PMID: 33446568 DOI: 10.1101/gad.344184.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhu J, Wang H, Chen F, Fu J, Xu Y, Hou Y, Kou HH, Zhai C, Nelson MB, Zhang Q, Andersen ME, Pi J. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. Free Radical Biology and Medicine 2016;99:544-56. [DOI: 10.1016/j.freeradbiomed.2016.09.010] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 16.7] [Reference Citation Analysis]
22 Gonzalez-Perez A. Circuits of cancer drivers revealed by convergent misregulation of transcription factor targets across tumor types. Genome Med 2016;8:6. [PMID: 26792175 DOI: 10.1186/s13073-015-0260-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Xiang Y, Dai S, Li D, Zhu X, Su J, Chen B, Wu M. Brusatol inhibits the invasion and migration of pancreatic cancer cells by suppressing the NRF2/NF-κB/STAT3 signal cascade. Journal of Functional Foods 2022;92:105024. [DOI: 10.1016/j.jff.2022.105024] [Reference Citation Analysis]
24 Durymanov M, Permyakova A, Reineke J. Pre-treatment With PLGA/Silibinin Nanoparticles Mitigates Dacarbazine-Induced Hepatotoxicity. Front Bioeng Biotechnol 2020;8:495. [PMID: 32671024 DOI: 10.3389/fbioe.2020.00495] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi S, Jin K, Liang D, Xu W, Xu H, Wang W, Wu C, Liu L, Liu C, Xu J, Ni Q, Yu X. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett 2016;374:127-35. [PMID: 26854714 DOI: 10.1016/j.canlet.2016.01.054] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
26 Endo S, Matsunaga T, Nishinaka T. The Role of AKR1B10 in Physiology and Pathophysiology. Metabolites 2021;11:332. [PMID: 34063865 DOI: 10.3390/metabo11060332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Kha ML, Hesse L, Deisinger F, Sipos B, Röcken C, Arlt A, Sebens S, Helm O, Schäfer H. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2. Oncogene 2019;38:1461-76. [PMID: 30302023 DOI: 10.1038/s41388-018-0518-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Avdović EH, Petrović IP, Stevanović MJ, Saso L, Dimitrić Marković JM, Filipović ND, Živić MŽ, Cvetić Antić TN, Žižić MV, Todorović NV, Vukić M, Trifunović SR, Marković ZS. Synthesis and Biological Screening of New 4-Hydroxycoumarin Derivatives and Their Palladium(II) Complexes. Oxid Med Cell Longev 2021;2021:8849568. [PMID: 34007407 DOI: 10.1155/2021/8849568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Li J, Wang Q, Yang Y, Lei C, Yang F, Liang L, Chen C, Xia J, Wang K, Tang N. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. J Exp Clin Cancer Res 2019;38:438. [PMID: 31666108 DOI: 10.1186/s13046-019-1459-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]